Cidara Therapeutics

180 articles with Cidara Therapeutics

• 

  Cidara and Melinta Win FDA Approval for First New Echinocandin in a Decade

  3/23/2023

  Wednesday, the FDA approved Cidara Therapeutics and Melinta Therapeutics’ Rezzayo (rezafungin) injection to treat candidemia and invasive candidiasis.

• Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

  3/23/2023

  Cidara Therapeutics, Inc. today reported financial results for the three months and full year ended December 31, 2022 and provided an update on its corporate activities and product pipeline.

• Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis

  3/22/2023

  Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.

• 

  FDA Action Alert: Biogen/Ionis, Cidara and Incyte

  3/20/2023

  An advisory committee will meet March 22 to discuss the fate of Biogen and Ionis’ ALS hopeful tofersen. For that and more, see inside.

• Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress

  3/7/2023

  Cidara Therapeutics, Inc. presented preclinical data on a CD73-targeting drug-Fc conjugate (DFC) candidate, CBO-212, from the Company’s Cloudbreak ® platform, at the ESMO Targeted Anticancer Therapies Congress (ESMO TAT) in Paris, March 6-8, 2023.

• Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares in Public Offering of Common Stock

  3/7/2023

  Cidara Therapeutics, Inc. today announced the closing of its previously announced concurrent but separate underwritten public offerings of 11,086,000 shares of its common stock, including the exercise in full by the underwriter of its option to purchase an additional 1,446,000 shares of common stock.

• Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock

  3/3/2023

  Cidara Therapeutics, Inc. today announced the pricing of concurrent but separate underwritten public offerings of 9,640,000 shares of its common stock and 286,000 shares.

• Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock

  3/2/2023

  Cidara Therapeutics, Inc. announced concurrent but separate underwritten public offerings of its common stock and its Series X Convertible Preferred Stock.

• Cidara Therapeutics Announces Promising Interim Phase 2a Data Assessing the Safety and Efficacy of a Single Dose of CD388 in an Influenza Challenge Model

  3/1/2023

  Cidara Therapeutics, Inc. today announced promising efficacy and safety data from a planned interim analysis of the ongoing Phase 2a trial evaluating the pre-exposure prophylactic activity of CD388 against the H3N2 influenza A virus strain, as of a February 13, 2023 data cut-off.

• Cidara to Present at ESMO Targeted Anticancer Therapies Congress

  2/28/2023

  Cidara Therapeutics, Inc. today announced that it will present highlights from pharmacokinetic studies of a CD73-targeting drug-Fc conjugate (DFC) oncology candidate from the Company’s Cloudbreak ®  platform at the ESMO Targeted Anticancer Therapies Congress (ESMO TAT) in Paris, March 6-8, 2023.

• Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - February 14, 2023

  2/14/2023

  Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, announced that it has received formal notice from The Nasdaq Stock Market, LLC, stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550.

• Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara’s CD73 Oncology DFC Program

  2/1/2023

  Cidara Therapeutics, Inc. and WuXi XDC announced an expansion of their existing collaboration under which WuXi XDC will provide investigational new drug -enabling chemistry, manufacturing and controls development services for Cidara’s CD73 oncology DFC program.

• Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

  1/25/2023

  Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee voted favorably 14 to 1 that Cidara, as part of its New Drug Application (NDA).

• Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® PlatformCBO-212 is a first-in-class inhibitor of CD73 cancer immunotherapy target

  1/4/2023

  Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it has selected its first oncology drug-Fc conjugate (DFC) candidate from the company’s Cloudbreak® platform: CBO-212, targeting CD73.

• Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388Initial CD388 clinical data expected in the first half of 2023

  12/1/2022

  Cidara Therapeutics, Inc. (NASDAQ: CDTX) today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 11,510,992, entitled Compositions and Methods for the Treatment of Viral Infections, for CD388, a highly potent, long-acting drug-Fc conjugate (DFC) designed to achieve universal prevention of seasonal and pandemic influenza.

• Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split

  11/29/2022

  Cidara Therapeutics, Inc. announced that Institutional Shareholder Services and Glass Lewis and Co, LLC, two leading, independent proxy advisory firms, have both recommended that stockholders vote “FOR” the proposed reverse stock split at the Company’s upcoming Special Meeting of Stockholders, scheduled for Thursday, December 15, 2022 at 8:00 a.m. PST.

• Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet

  11/28/2022

  Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Melinta Therapeutics, LLC today announced the peer-reviewed publication of data from the completed pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential treatment for candidemia and invasive candidiasis.

• Cidara Therapeutics to Participate in the World Antiviral Congress 2022

  11/23/2022

  Cidara Therapeutics, Inc. today announced that Jeff Stein, Ph.D., President and CEO, will participate in a panel discussion at the World Antiviral Congress being held in San Diego, California from November 28-December 1, 2022.

• Cidara Therapeutics to Present at the Stifel Healthcare Conference

  11/8/2022

  Cidara Therapeutics, Inc. announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare Conference.

• Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

  11/3/2022

  Cidara Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2022 and provided an update on its corporate activities and product pipeline.